Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan.
Suzuran Hospital, Kobe, Japan.
Kobe J Med Sci. 2021 Dec 21;67(3):E112-E118.
Hemodialysis patients often develop constipation. We analyzed the advantage of synbiotics over prebiotics based on the stool form due to the intestinal environment in hemodialysis patients. Patients received either synbiotics or prebiotics for four weeks. The synbiotics group was treated with partially hydrolyzed guar gum containing Bifidobacterium longum BB536, while the prebiotics group was treated with the same fiber alone. The defecation status was assessed using the Bristol Stool Form Scale and abdominal bloating was evaluated using a visual analog scale. The fecal microbiota, measured by a terminal restriction fragment length polymorphism analysis, and the fecal short-chain fatty acid concentrations, measured by gas chromatography, were compared between the two groups. Synbiotics ingestion improved the individual stool form and abdominal bloating, and increased Bifidobacterium, which produces short-chain fatty acid, 13.9-fold after ingestion. In particular, acetic acid increased 2.5-fold in the synbiotics group. On the other hand, butyric acid increased 3.0-fold in the prebiotics group. Synbiotics improved the stool form in hemodialysis patients due to the composition of the intestinal microbiota and short-chain fatty acid concentrations.
血液透析患者常发生便秘。我们根据血液透析患者的肠道环境,基于粪便形态分析了合生制剂相对于益生元的优势。患者接受合生制剂或益生元治疗 4 周。合生制剂组用含有长双歧杆菌 BB536 的部分水解瓜尔胶治疗,而益生元组仅用相同的纤维治疗。使用布里斯托粪便形态量表评估排便情况,使用视觉模拟量表评估腹部胀气。通过末端限制性片段长度多态性分析比较两组粪便微生物群,通过气相色谱法比较粪便短链脂肪酸浓度。合生制剂摄入可改善个体粪便形态和腹部胀气,并使产生短链脂肪酸的双歧杆菌增加 13.9 倍。特别是,乙酸在合生制剂组增加了 2.5 倍。另一方面,丁酸在益生元组增加了 3.0 倍。合生制剂通过肠道微生物群组成和短链脂肪酸浓度改善了血液透析患者的粪便形态。